ArticleTranslational andrology and urology2025
Efficacy of cystectomy in single-site oligometastatic bladder cancer: a Surveillance, Epidemiology, and End Results (SEER) study of 1,381 patients.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The treatment paradigm of metastatic bladder cancer has remained largely unchanged for decades and the prognosis is extremely poor. This study aimed to evaluate the role of cystectomy in patients with single-site oligometastatic bladder cancer. Methods: Patients with single-site distant metastasis at the time of bladder cancer diagnosis from 2010-2017 were identified from Surveillance, Epidemiology, and End Results (SEER) database. Cohorts were defined by target organ [bone, brain, lung, liver, distant lymph nodes (DLNs)] and then stratified by local treatment received [no surgery, transurethral resection of bladder tumor (TURBT) and cystectomy]. Patients not receiving chemotherapy were excluded. Two-year cancer specific survival (CSS) was assessed using Kaplan-Meier (K-M) analysis and multivariable Cox proportional hazards analysis, adjusting for demographic, clinical and pathologic factors. Results: A total of 1,381 patients met study criteria. K-M analysis indicated that cystectomy was associated with improved survival when compared to no surgery in patients with bone and DLNs metastasis. In multivariable analysis, patients with bone [hazard ratio (HR) =0.58; P=0.03] or DLNs (HR =0.51; P=0.005) metastasis who underwent cystectomy had a significant survival advantage over those receiving systemic therapy only. And patients with liver (HR =0.40; P=0.07) and lung (HR =0.84; P=0.58) who underwent cystectomy failed to exhibit superior survival than those receiving chemotherapy only. Patients with brain metastasis were omitted in subgroup analysis due to the limit of small sample size (n=20). In addition, the advent of immune checkpoint inhibitors improved the survival of patients, with HR of 0.78, indicating the reduction of death risk by 22%. Conclusions: Cystectomy in the setting of multimodality protocols may prolong survival in bladder cancer patients with single-site metastasis of the bone and DLNs. It should be considered in a multidisciplinary setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.